Department of Clinical Pharmacy, Pharmaceutical Sciences Research Centre, School of Pharmacy, Tehran University of Medical Sciences, Tehran, Iran.
Eur Rev Med Pharmacol Sci. 2013 Apr;17(7):964-70.
Nitric oxide (NO) and its toxic product peroxynitrite contribute to oxidative stress and neurodegeneration in Parkinson's disease (PD). The relationship of serum levels of these oxidants with the severity of the disease [evaluated by the Unified Parkinson's Disease Rating Scale (UPDRS)] is not established.
This study was designed to evaluate whether patients with PD had higher NO and peroxynitrite serum level or not.
Fifty eight patients with PD and 15 healthy volunteers entered this study. The concentrations of serum NO and peroxynitrite were assayed and their correlation with the UPDRS score was assessed.
Mean serum NO levels in patient group was 29.8 ± 21.631 versus 7.49 ± 2.573 in control group, which was significantly higher in patients (p ≤ 0.0001). Peroxynitrite levels in patient and control groups were 7.37±3.501 µmol/L and 3.94 ±1.389 µmol/L respectively. Patients had a significantly higher peroxynitrite level (p = 0.0004).
Higher levels of NO and peroxynitrite leads to higher UPDRS scores. It seems since current PD treatments do not affect the pathology of the disease, using drugs that exert neuroprotective properties should be considered for the treatment of PD in order to prevent further neuronal cell loss.
一氧化氮（NO）及其有毒产物过氧亚硝酸盐导致帕金森病（PD）中的氧化应激和神经退行性变。这些氧化剂的血清水平与疾病的严重程度（通过统一帕金森病评定量表（UPDRS）评估）之间的关系尚未确定。
本研究旨在评估 PD 患者是否具有更高的血清 NO 和过氧亚硝酸盐水平。
58 名 PD 患者和 15 名健康志愿者参与了这项研究。测定了血清 NO 和过氧亚硝酸盐的浓度，并评估了它们与 UPDRS 评分的相关性。
患者组的血清 NO 水平平均值为 29.8 ± 21.631，对照组为 7.49 ± 2.573，患者组明显更高（p ≤ 0.0001）。患者组和对照组的过氧亚硝酸盐水平分别为 7.37±3.501 µmol/L 和 3.94 ±1.389 µmol/L。患者的过氧亚硝酸盐水平明显更高（p = 0.0004）。
更高水平的 NO 和过氧亚硝酸盐导致更高的 UPDRS 评分。由于目前的 PD 治疗方法不能影响疾病的病理，因此应该考虑使用具有神经保护作用的药物来治疗 PD，以防止进一步的神经元细胞丢失。
